Elevance Health stock gains as FY 2026 EPS guidance trails consensus slightly
Published on 09/19/2026 at 17:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health Inc. stock (ISIN US2855211023) is trading around USD 410 on the New York Stock Exchange as of September 18, 2026, valuing the United States health insurer at roughly USD 89.9 billion and reflecting modest gains in recent weeks. As MarketBeat reported on September 19, 2026, the company has issued FY 2026 earnings per share guidance of USD 27.00, slightly below the analyst consensus estimate of USD 27.16, a nuance that investors are now weighing against strong recent earnings momentum.
FY 2026 EPS guidance and recent earnings beat
According to MarketBeat on September 19, 2026, Elevance Health provided FY 2026 EPS guidance of USD 27.00, compared with the consensus earnings estimate of USD 27.16, signaling a cautious stance that nonetheless remains close to market expectations. The same overview notes that in the latest reported quarter the company delivered EPS of USD 7.45, clearly ahead of expectations of USD 6.21, meaning Elevance Health beat consensus by USD 1.24 per share in that period, a solid positive surprise for shareholders. In addition, Elevance Health announced a quarterly dividend of USD 1.72 per share, equivalent to an annualized USD 6.88 and implying a dividend yield of about 1.7 percent on the current share price, with the payout ratio stated at 30.58 percent, underlining that the company retains ample earnings capacity for reinvestment and balance sheet strength.
The guidance update contrasts only slightly with the consensus view, so the quantified comparison between USD 27.00 guided EPS and USD 27.16 expected EPS is small in absolute terms but important as a signal that management is not stretching the outlook. For investors, the larger takeaway is the recent quarterly outperformance where EPS of USD 7.45 exceeded the USD 6.21 consensus by about 20 percent, suggesting operational momentum that may give Elevance Health room to absorb macroeconomic or regulatory headwinds while still meeting or beating its full year targets.
Analyst ratings, price targets and valuation backdrop
As MarketBeat also highlights on September 19, 2026, Elevance Health stock carries a consensus rating of Moderate Buy, with fifteen analysts assigning a Buy recommendation and eight rating the shares Hold, reflecting a broadly favorable but not euphoric stance on the managed care group. The consensus 12 month price target stands at USD 440.90, which is roughly USD 30 above the recent trading area around USD 410, indicating that analysts on average still see upside from current levels despite the slightly conservative FY 2026 EPS guidance. In the same profile, Elevance Health is described as trading with a 12 month low of USD 274.84 and a 12 month high of USD 436.24, meaning the current price near USD 410 sits well above the low and moderately below the high, situating the stock in the upper portion of its recent range.
Per data cited by MarketBeat, shares of Elevance Health opened around USD 410.71 on the most recent trading day covered, with a 50 day simple moving average of USD 397.09 and a 200 day simple moving average of USD 369.87, illustrating that the stock is trading above both medium term and longer term trend lines. For investors, the combination of a Moderate Buy consensus rating, an average price target of USD 440.90 and a share price in the low USD 410 area as of September 18, 2026 suggests some headroom before the consensus target while still acknowledging that much of the recent earnings strength is already reflected in the valuation.
Dividend, legal risks and sector context
The dividend profile is another anchor for Elevance Health stock. According to MarketBeat, the quarterly dividend of USD 1.72 per share, scheduled for payment on September 25 in the current distribution cycle, yields 1.7 percent on an annualized basis and corresponds to a payout ratio of 30.58 percent, which leaves nearly 70 percent of earnings available for growth initiatives or balance sheet flexibility. For income oriented investors, the combination of this yield with strong EPS growth can be attractive, especially when the stock trades near the upper end of its 12 month range but still below the consensus price target.
At the same time, risks are visible. As Law360 reported on September 18, 2026, a practice group of independent neurosurgeons has filed an antitrust lawsuit against Elevance Health Inc., alleging that a penalty policy for out of network surgeries is anticompetitive and harms competition for specialist care in New York. While the financial impact of this litigation is not yet quantified, such legal challenges can represent overhangs for health insurers because adverse rulings could lead to changes in reimbursement structures, fines or reputational effects that ultimately influence earnings trajectories and investor sentiment.
Against this backdrop, Elevance Health operates in the managed care segment of the United States health care sector, where regulatory oversight, competitive dynamics and political debates over reimbursement and network adequacy are persistent factors. The strong recent EPS beat of USD 7.45 versus USD 6.21 consensus in the latest quarter, together with a solid dividend and Moderate Buy analyst consensus, suggests the company is currently navigating this environment successfully, but the slightly lower FY 2026 EPS guidance relative to consensus and the newly reported antitrust suit indicate that management and investors are aware of potential pressure points in the coming quarters.
Stock level and trading data as of September 18, 2026
Per recent trading data as of September 18, 2026, Elevance Health stock changed hands at around USD 414.26 on the New York Stock Exchange, with an intraday high near USD 418.77 and an intraday low around USD 411.45, implying a daily range of about USD 7.32 and placing the closing level modestly below the session high while clearly above the low. In the same session, the shares reflected a market capitalization of approximately USD 89.86 billion in United States dollars, underlining the company’s position as one of the larger managed care players in the S&P 500 index. For investors looking at the chart, the fact that the price around USD 414 sits considerably above the 12 month low of USD 274.84 yet still below the 12 month high of USD 436.24 indicates that Elevance Health stock is trading closer to the upper third of its yearly range but has not yet retested its recent peak.
Elevance Health stock key data
- Company: Elevance Health Inc.
- ISIN: US2855211023
- Ticker: ELV
- Trading venue: NYSE
- Price (as of September 18, 2026): 414.26 USD
- Market capitalization: 89.86 billion USD (as of September 18, 2026)
- Sector / Industry: Health Care / Managed Care
- Index membership: S&P 500
